Skip to main content

Table 1 Patient demographics and baseline characteristics (randomized population)

From: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

 

Rosuvastatin 10 mg (n = 504)

Atorvastatin 20 mg (n = 492)

Mean age, years (SD)

60.2 (10.4)

60.7 (10.6)

Male gender, n (%)

273 (54.2)

285 (57.9)

Mean BMI, kg/m2 (SD)

29.7 (5.6)

29.7 (5.9)

Race, n (%)

  

   Caucasian

376 (74.6)

380 (77.2)

   Hispanic

98 (19.4)

90 (18.3)

   Black

23 (4.6)

17 (3.5)

   Asian

6 (1.2)

3 (0.6)

   Other

1 (0.2)

2 (0.4)

Renal function*, n (%)

  

   Normal

292 (57.9)

271 (55.1)

   Mild impairment

177 (35.1)

190 (38.6)

   Moderate impairment

35 (6.9)

29 (5.9)

Metabolic syndrome†, n (%)

254 (50.4)

237 (48.2)

Diabetes (type 1 or 2), n (%)

256 (50.8)

250 (50.8)

CHD or CHD-risk equivalents, n (%)

431 (85.5)

407 (82.7)

Patients without CHD or a CHD-risk equivalent, n (%)

72 (14.3)

85 (17.3)

   Framingham 10-year risk > 20%

30 (6.0)

32 (6.5)

   Framingham 10-year risk ≥ 10% and ≤ 20%

17 (3.4)

25 (5.1)

   Framingham 10-year risk < 10%

25 (5.0)

28 (5.7)

  1. SD, standard deviation; BMI, body mass index; CHD, coronary heart disease; NCEP ATP, National Cholesterol Education Program Adult Treatment Panel; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.
  2. *Renal function assessed using creatinine clearance as follows: > 80 mL/min (normal), 50 to ≤ 80 mL/min (mild impairment), 30 to < 50 mL/min (moderate impairment). Creatinine clearance was calculated from serum creatinine using the following equations: creatinine clearance (mL/min) = ([140-age at visit 4] × weight at visit 1 [kg])/72 × serum creatinine at visit 4 (mmol/L) × 0.01131 if male; or creatinine clearance (mL/min) = ([140-age at visit 4] × weight at visit 1 [kg])/85 × serum creatinine at visit 4 (mmol/L) × 0.01131 if female.
  3. †Modified NCEP ATP III definition [6]: Patients fulfill at least 3 of the following 5 criteria: fasting blood glucose ≥ 6.1 and ≤ 6.9 mmol/L (110 and 125 mg/dL); waist circumference > 102 cm (male) or > 88 cm (female); TG ≥ 1.7 mmol/L (150 mg/dL); HDL-C < 1.0 mmol/L (40 mg/dL) in men or < 1.3 mmol/L (50 mg/dL) in women; and hypertension (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg) or taking antihypertensive medication.
Back to article page

Trials

ISSN: 1745-6215